Presenting research at a prestigious symposium like ASCO can be seen as a validation of Aadi Bioscience's work and may raise its profile in the oncology community. This could lead to increased interest from investors and possibly impact the stock price positively in the short term. However, the actual content and reception of the presentations will ultimately determine the extent of the impact.